Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 7/20 | 0.64 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11193326 | 0.90 | CYP2A13 (0.75) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL17585440 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL20237811 | 0.82 | ALDH1A1 (0.53) | NCF1ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL29668891 | 0.82 | ALDH1A1 (0.53) | NCF1ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL3738488 | 0.81 | CYP2A13 (0.69) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL22711364 | 0.81 | CYP2A13 (0.64) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL4108619 | 0.81 | CYP2A13 (0.69) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL2338990 | 0.81 | CYP2A13 (0.64) | CYP2A13NCF1ALDH1A1CYP2C9KMT2A | |
| SCHEMBL2251851 | 0.81 | CYP2A13 (0.64) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL21800082 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | claimed |
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2021-08-03 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009078-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-0420883-B1 | TRICYCLIC 3-OXO-PROPANENITRILE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ERBA CARLO SPA (IT) | 1993-11-03 | — | — | EP | disclosed |
| US-5166152-A | Immunostimulants, bactericides, viricides, antitumor agents | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-11-24 | — | — | US | disclosed |
| EP-0420883-A1 | TRICYCLIC 3-OXO-PROPANENITRILE DERIVATIVES AND PROCESS FOR THEIR PREPARATION. | ERBA CARLO SPA (IT) | 1991-04-10 | — | — | EP | disclosed |
| WO-1989012638-A1 | TRICYCLIC 3-OXO-PROPANENITRILE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-12-28 | — | — | WO | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | CYP2A13 1200/4885NCF1 1648/4885ALDH1A1 2743/4885 |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | CYP2A13 2294/4885NCF1 2713/4885ALDH1A1 2351/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | CYP2A13 1200/4885NCF1 1648/4885ALDH1A1 2743/4885 |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | CYP2A13 2294/4885NCF1 2713/4885ALDH1A1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.